Journal article
Interleukin-6 promoter variants, prostate cancer risk, and survival
EA Tindall, G Severi, HN Hoang, MC Southey, DR English, JL Hopper, GG Giles, VM Hayes
Prostate | Published : 2012
DOI: 10.1002/pros.22557
Abstract
Background. Inflammation has been implicated in prostate cancer (PCa) pathogenesis. Promoter DNA variants responsible for differential expression of key cytokines may therefore influence susceptibility to PCa. Methods. Two interleukin-6 (IL-6) promoter variants, -174G>C and -6331T>C, were genotyped for association with PCa risk and survival using the Risk Factors for Prostate Cancer Study (RFPCS, 825 cases and 732 controls) and the Melbourne Collaborative Cohort Study (MCCS, 818 cases and 1,745 controls). Impact of genotypes on IL-6 transcriptional activity was measured using Low Density Arrays. RESULTS A significant increase in IL-6 transcriptional activity in malignant compared to benign p..
View full abstractRelated Projects (2)
Grants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
[ "Grant sponsor: National Health and Medical Research Council; Grant numbers: 396407, 504700, 504702, 614296; Grant sponsor: Cancer Institute of New South Wales; Grant sponsor: Australian Rotary Health Foundation; Grant sponsor: Prostate Cancer Foundation Australia.", "This study was supported by grants from the National Health and Medical Research Council (project grants #396407, #504700, and #504702 and Fellowships to E. A. T., M. S. C., and J.L.H.), Cancer Institute of New South Wales Grant (to V. M. H.) and Fellowships (to E. A. T. and V. M. H.), and an Australian Rotary Health Fellowship (to E. A. T.). Infrastructure support was provided from the Children's Cancer Institute Australia, The Cancer Council Victoria and The University of Melbourne. The Australian Prostate Cancer BioResource is supported by an Enabling Grant from the NHMRC (#614296). We are grateful to the study participants, as well as the many urologists, nurses, and pathologists who kindly facilitated in the recruitment and collection of patient information and pathology reports. We would also like to thank the Australian Prostate Cancer BioResource (APCB, http://www.apccbioresource.org.au/) for providing the prostate tissue samples." ]